Agenus (NASDAQ: AGEN) is one of 186 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Agenus to similar companies based on the strength of its dividends, institutional ownership, analyst recommendations, profitability, earnings, valuation and risk.
This is a summary of current ratings and recommmendations for Agenus and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Agenus currently has a consensus price target of $6.33, indicating a potential upside of 67.99%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.32%. Given Agenus’ stronger consensus rating and higher probable upside, analysts plainly believe Agenus is more favorable than its competitors.
Insider and Institutional Ownership
37.9% of Agenus shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 7.9% of Agenus shares are owned by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Agenus has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, Agenus’ competitors have a beta of 1.57, suggesting that their average share price is 57% more volatile than the S&P 500.
Valuation & Earnings
This table compares Agenus and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Agenus||$22.57 million||-$126.99 million||-3.22|
|Agenus Competitors||$217.29 million||-$39.39 million||-69.11|
Agenus’ competitors have higher revenue and earnings than Agenus. Agenus is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Agenus and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Agenus competitors beat Agenus on 7 of the 12 factors compared.
Agenus Company Profile
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company’s vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.